Key facts
- Andson Biotech’s last known valuation is $17.5M (Oct 2025).
- It has raised $9.0M across 2 recorded rounds; the latest was Seed Round ($4.7M) in Oct 2025.
- Notable investors include Y Combinator, MedTech Innovator, Gaingels, BioTools Innovator, Biolocity — 10 tracked in total.
- Andson Biotech has filed 1 Form D with the SEC, most recently Mar 2024 ($3.6M sold to 37 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Andson Biotech
Funding rounds
2 roundsAbout Andson Biotech
Developer of a novel Process Analytical Technology (PAT) designed for cell-based bioprocesses. The company uses a secretome analysis system and its core technologies to accelerate and simplify common analytical measurements carried out by conventional mass spec workflows and develops assays to telescope the drug discovery process and get advanced therapies to market, enabling healthcare professionals with recombinant proteins, monoclonal antibodies, and vaccines.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2020
- Employees
- 10
- Website
- andsonbiotech.com/
- Ownership
- Privately Held (backing)
Andson Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Andson Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Andson Biotech in its N-PORT filings yet. We sweep new filings monthly.